Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins
Accession Number
DB15729
Description

Adipose mesenchymal stem cells (AMSCs) are MSCs derived from adipose tissue, which is more accessible and less painful than stem cells extracted from most other sources. Autologous stem cells are those derived from a patient’s own cells while allogeneic stem cells are derived from that of a donor. Lipoaspiration, also known as liposuction, is a possible method for extraction. This is followed by purification and expansion of the cells in vitro.

These AMSCs are multipotent, with the capability of forming different tissues, some of which include bone, muscle, neural, and chondrocyte. This explains why AMSCs have been utilized in repairing craniofacial bone defects. They also have potential in treatment of scarred vocal folds.

Type
Biotech
Groups
Investigational
Biologic Classification
Cell transplant therapies
Autologous cell transplant / Other cell transplant therapies
Synonyms
  • CMTAd
  • HB-adMSCs
  • HCR040
  • PSC-04
External IDs
  • Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action

AMSCs have been shown to secrete several growth factors and hyaluronic acid (HA) which balance collagen, with hepatocyte growth factor (HGF) being a major part of those secreted. HGF secreted by AMSCs has been shown, in culture, to attenuate collagen production and fibroblast proliferation. AMSCs also have the ability to produce elastic fibers, something that typically does not appear in a scar environment.

In some studies, adipose mesenchymal stem cells have demonstrated anti-inflammatory and chondroprotective properties. Currently, the exact mechanism behind AMSCs is unknown. However, a possible mechanism consists of activation of the cells due to inflammation, with the activated cells then modulating inflammation and cartilage remodeling by prostaglandin E2. The effects for AMSCs seem to also possibly be dose-dependent.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Categories

Drug Categories
Not Available
Classification
Not classified

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. Mazini L, Rochette L, Amine M, Malka G: Regenerative Capacity of Adipose Derived Stem Cells (ADSCs), Comparison with Mesenchymal Stem Cells (MSCs). Int J Mol Sci. 2019 May 22;20(10). pii: ijms20102523. doi: 10.3390/ijms20102523. [PubMed:31121953]
  2. Zakrzewski W, Dobrzynski M, Szymonowicz M, Rybak Z: Stem cells: past, present, and future. Stem Cell Res Ther. 2019 Feb 26;10(1):68. doi: 10.1186/s13287-019-1165-5. [PubMed:30808416]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Active Not RecruitingTreatmentNovel Coronavirus Infectious Disease (COVID-19)1
2Enrolling by InvitationPreventionNovel Coronavirus Infectious Disease (COVID-19)2
1Not Yet RecruitingTreatmentNovel Coronavirus Infectious Disease (COVID-19)1
1, 2Active Not RecruitingTreatmentAcute Respiratory Distress Syndrome (ARDS)1
1, 2Active Not RecruitingTreatmentAlzheimer's Disease (AD)1
1, 2Active Not RecruitingTreatmentRheumatoid Arthritis1
1, 2RecruitingTreatmentTraumatic Brain Injury (TBI)1
Not AvailableAvailableNot AvailableAmyotrophic Lateral Sclerosis (ALS)1
Not AvailableNo Longer AvailableNot AvailableCerebral Palsy (CP)1
Not AvailableNo Longer AvailableNot AvailableMalignant Neoplasm of Pancreas1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on August 11, 2020 13:09 / Updated on August 13, 2020 01:02

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates